FindTrial
Sign In

The effect to the pulmonary function in breast cancer patients who received neoadjuvant chemotherapy

The effect to the pharmacodynamics of muscle relaxant in breast cancer patients who received neoadjuvant chemotherapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPB-15007187
Enrollment
Unknown
Registered
2015-10-09
Start date
2015-10-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

effects of neoadjuvant chemotherapy on pulmonary function of breast cancer patients

Interventions

control group:none
combined chemotherapy group:4 cycles of doxorubicin, 5-Fu andcyclophosphamide
taxol group:4 cycles of taxol

Sponsors

Beijing Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. patients aged 20-60 years old; 2. ASA grade I-II; 3. female breast cancer patients

Exclusion criteria

Exclusion criteria: 1. neuromuscular disorder; 2. received a second operation at the time of hospitalization; 3. the history of respiratory system disease; 4. obesity (BMI>=31); 5. pregnant woman; 6. patients refuse to participate the study; 7. the researchers believe that there is any situation that is not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
FVC;FEV1;FEV1/FVC;FEF25-75%;TLC Sb;RV Sb;VC;VE;Vt;DLCO;QLQ-C30(V3.0) questionnaire;—

Secondary

MeasureTime frame
neuropathy questionnaire;—

Countries

China

Contacts

Public ContactHe Zi-jing
hezijing2006@126.com+86 13601315172

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026